...
首页> 外文期刊>Transplantation Proceedings >Liver transplantation for hepatocellular carcinoma within milan criteria in patients with model for end-stage liver disease score below 15: The impact of the etiology of cirrhosis on long-term survival
【24h】

Liver transplantation for hepatocellular carcinoma within milan criteria in patients with model for end-stage liver disease score below 15: The impact of the etiology of cirrhosis on long-term survival

机译:终末期肝病模型得分低于15的患者中符合米兰标准的肝细胞癌肝移植:肝硬化的病因对长期生存的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Liver transplantation (OLT) is the gold standard therapy for patients with cirrhosis complicated by hepatocellular carcinoma (HCC) within Milan Criteria (MC). We evaluated the impact of the etiology of the underlying liver disease on long-term outcomes of patients undergoing OLT for HCC within MC having a Model for End-stage Liver Disease (MELD) score < 15. Methods From November 2002 to December 2009, we performed 203 primary OLTs from brain-dead donors in recipients with HCC and cirrhosis with biochemical MELD scores below 15. We excluded 31 patients outside MC on the explant pathology of the native liver. The remaining 172 were divided into 3 groups according to the etiology of the underlying cirrhosis: hepatitis C virus-positive (HCV+; n = 78; 45%), hepatitis B virus-positive (HBV+; n = 65; 38%) and other indications (n = 29; 17%). The groups were compared for donor and recipient features, donor-recipient match, and transplant variables. The study endpoint was long-term patient survival. Results The groups were similar, except for a greater prevalence of hepatitis B core antibody-positive grafts in the HBV+ group and less frequent HCC bridging procedures in the other indications group. After a median follow-up of 72 months, HCC recurrence was observed in 8 (4.7%) patients (6 HCV+, 2 other indications), 5 of whom died. Overall 5-year patient survival of 82%, revealed significant differences among groups: 98.3% in HBV+, 67.1% in HCV+, and 85.8% in other indications (HBV+ vs other indications: P =.01; HBV+ vs HCV+: P =.0001; HCV+ vs other indications: P = NS). In the HCV+ group, recurrent HCV hepatitis was the most frequent cause of death. Upon multivariate analysis, HBV positivity in the recipient was an independent predictor of better patient survival (hazard ratio = 0.10, 95% confidence interval 0.02-0.64, P =.013). Conclusions Etiology of the underlying cirrhosis significantly influenced the long-term survival after OLT of patients with HCC within MC and MELD < 15. It should be taken into account in estimation of survival benefit.
机译:背景技术米兰标准(MC)规定,肝移植(OLT)是肝硬化并发肝细胞癌(HCC)患者的金标准疗法。我们评估了基础肝病的病因对终末期肝病(MELD)得分<15的MC内接受OLT接受HCC的患者的长期结局的影响。方法从2002年11月至2009年12月,我们他们在患有肝癌和肝硬化的生化MELD得分低于15的接受者中,从脑死亡供者中进行了203例原发性OLT。在自然肝脏的外植体病理学上,我们排除了MC以外的31例患者。其余的172根据潜在肝硬化的病因分为三类:丙型肝炎病毒阳性(HCV +; n = 78; 45%),乙型肝炎病毒阳性(HBV +; n = 65; 38%)和其他适应症(n = 29; 17%)。比较各组的供体和受体特征,供体-受体匹配和移植变量。研究终点是患者的长期生存。结果各组相似,除了HBV +组中乙型肝炎核心抗体阳性移植物的患病率较高,而其他适应症组中的HCC桥接程序较少。中位随访72个月后,在8例(4.7%)患者中观察到HCC复发(6 HCV +,另外2项适应症),其中5例死亡。总体5年患者生存率为82%,各组之间存在显着差异:HBV + 98.3%,HCV + 67.1%和其他适应症85.8%(HBV +与其他适应症:P = 0.01; HBV +与HCV +:P =。 0001; HCV +与其他指标:P = NS)。在HCV +组中,复发性HCV肝炎是最常见的死亡原因。经过多变量分析,接受者的HBV阳性是患者存活率提高的独立预测因子(危险比= 0.10,95%置信区间0.02-0.64,P = .013)。结论潜在肝硬化的病因显着影响MC和MELD <15内HCC患者OLT术后的长期生存。在评估生存获益时应考虑到这一点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号